How to provide consent for operational information sharing

Marketing Authorisation (MA) Applicants submitting relevant regulatory Marketing Authorisation Applications (MAAs) will be asked to provide consent to share operational information (<u>https://www.gov.uk/government/publications/operational-information-sharing</u>) with cross-UK health system partners during the MAA process on the MHRA's Human Medicines Portal (HM Portal).

This guide shows how consent will be requested via the HM Portal during the MAA submission process, and how MA applicants can provide consent to share operational information during the MAA process.

Consent to share operational information must be provided by, or on behalf of, an authorised signatory who is able to provide the assurances required on behalf of the proposed Marketing Authorisation Holder (MAH).

For any further queries please contact partnerships @mhra.gov.uk.

- 1. Please follow the relevant guidance that explains how to submit MAA for medicines via the HM Portal (available at "Webinars: information on how to make submissions to the MHRA GOV.UK (<u>www.gov.uk</u>)" in <u>https://www.gov.uk/guidance/webinars-information-on-how-to-make-submissions-to-the-mhra</u>).
- 2. After selecting 'Submit application' in the appropriate page, the next screen of the application submission process captures the regulatory activity. Please proceed with your application filling in the 'Regulatory Area' section in accordance with the above guidance and as required for your application.
- 3. For your information, consent to share operational information will only be requested for 'Human Medicines' applications when one of the following options are selected from the drop-down list in 'Regulatory Activity' along with '**Original Submission**' from the 'Regulatory Sub Activity' drop-down list during the MAA process.
- 'Initial Marketing Authorisation NAS National'
- 'Initial Marketing Authorisation NAS IR Route A'
- 'Initial Marketing Authorisation NAS IR Route B'
- 'Variation Type II National (New Indication)'
- 'Variation Type II International Recognition (New Indication)'

•

Regulatory Area	Procedure	Em	25	Products	Supporting Documentation		
ser:		Area: *		Company: *			
		Human Medicines					
Regulatory Activity: *			Regulatory Sub Activity: *				
Select a regulatory activity			- Select a repulatory sub activity				
nomeopathic National Rules (NR)							
nformation Update							
nitial Marketing Authorisation - IR route A							
nitial Marketing Authorisation - IR route B							
nitial Marketing Authorisation Application - Nat	ional						
nibal Marketing Authorisation Application - Reli	lance					- A.	
nitial Marketing Authorisation NAS - IR route A							
nitial Marketing Authorisation NAS - IR route B							
nital Marketing Authorisation NAS - National							
atrosatnine Step 1							
iltrosamine Step 2							

Home

III ()

Regulatory Area	Procedure		Emails	Products	Supporting Documentation
Jser:		Area: *		Company: *	
		Human Medicines	•	Select a company	•
Regulatory Activity: *			Regulatory Sub Activity: *		
Select a regulatory activity			Select a regulatory sub activity		
Variation Type IB - Centralised UK(NI)			•		
Variation Type IB - International Recognition					
Variation Type IB - National					
Variation Type IB - Reliance/Recognition					
Variation Type II - Centralised UK(NI)					
Variation Type II - International Recognition (E	xcluding New Indication)				Æ
Variation Type II - International Recognition (N	lew Indication)				
Variation Type II - National (Excluding New Ind	lication)				
Variation Type II - National (New Indication)					
Variation Type II - Reliance/Recognition					
Withdrawal during assessment or withdrawal	of a marketing authorisation	on			

🛠 Home

Regulatory Area	Procedure	En	nalls	Products	Supporting Documentation		
User:		Area: *		Company: *			
		Human Medicines	•	- Select a company	•		
Regulatory Activity: *			Regulatory Sub Activity: *				
Select à regulatory activity			- Select a regulatory sub activity				
Comments:			Select a regulatory sub activity				
			CT - Amendment				
			CT-EOT				
			CT - GNA				
			CT - Initial CT - Summary of Results Original Submission				
			Response				
			Validation Correction Request (VCF	0			

🖌 Home

- 4. In the next steps of the MAA process, proceed with your application filling in the 'Procedure', 'Emails', 'Products' and 'Supporting Documents' as required per your application.
- 5. Following confirmation of upload of documents as required per your application, for the relevant MAAs detailed in point 2, the proposed MAH will be asked to provide consent to share operational information to support timely patient access to medicines as shown in the screen below.

Human Medicines Delivery File Subn	nission - Submission ID: 100185821				
Please click the 'CLOSE' button to c	lose the form and return to the prev	<i>r</i> ious menu.			
Please click the 'SUBMIT' button to	ensure that the submission has bee	n submitted successfully.			
					CLOSE PREVIOUS
Regulatory Area	Procedure	Emails	Products	Supporting Documentation	Submit
Validate and Confirm: DRAFT					
Valida	tion	Tab	Title	Status	
<		Regulat	tory Area	This form is co	omplete.

Procedure

Supporting Documentation

Consent to share operational information to support timely patient access to medicines

 \checkmark

 \checkmark

Please read the following statement carefully:

I have read MHRA's Operational Information Sharing Guidance and give my consent on behalf of the proposed Marketing Authorisation Holder to MHRA to share specific operational information with health system partners, both as indicated in the guidance.*

Consent to share operational information

⊖Yes ⊖No

By completing the 'Yes' selection above, you confirm that:

. You consent to share operational information with MHRA's health system partners, as indicated in the statement above.

• You have read MHRA's Operational Information Sharing Guidance

You are authorised by the proposed license holder to give this consent.

Where you have chosen not to consent to MHRA sharing operational information in accordance with the Operational Information Sharing Guidance, this will not affect MHRA's rights to hold, process or share your information insofar as it is required or permitted to do so under any applicable law, statute, regulation or legislation.

If you choose not to consent to share operational information in accordance with the Operational Information Sharing Guidance, you may still submit Marketing Authorisation applications and your current application will not be affected.

This form is complete.

This form is complete.

- 6. Click 'MHRA's Operational Information Sharing Guidance' to go to the gov.uk page (<u>https://www.gov.uk/government/publications/operational-information-sharing</u>) containing all the information about operational information sharing. Please read carefully the gov.uk page on Operational Information Sharing, and the Operational Information Sharing Guidance document on the linked page.
- Please ensure again that you are the appropriate person to give consent for operational information sharing. At this stage, if you are the / on behalf of the authorised signatory who is able to provide the assurances required on behalf of the proposed MAA select 'Yes', if you consent to operational information being shared with our health system partners as indicated in MHRA's Operational Information Sharing Guidance (<u>https://www.gov.uk/government/publications/operational-information-sharing</u>).

Home								
		Please click the 'SUBMIT' button to ensure that the submission has been submitted successfully. CLOSE PREVIOUS						
	Regulatory Area	Procedure	Emails	Products	Supporting Documentation	Submit		
	Validate and Confirm: DRAFT							
	Validation		Tab Title		Status			
	0		Regulatory Area		This form is complete.			
	0		Procedure		This form is complete.			
	0		Supporting Documentation		This form is complete.			
	Consent to share operational information to support timely patient access to medicines Please read the following statement carefully: There read MHRA's Operational Information Sharing Guidance and give my consent on behalf of the proposed Marketing Authorisation Holder to MHRA to share specific operational information with health system partners, both as indicated in the guidance.*							
	Consent to share operational inform	Consent to share operational information						
	By completing the Yes' selection above. You consent to share operational You have read MHRA's Operation You are authorised by the propo- Where you have chosen not to consent information insofar as it is required or p	By completing the Yes' selection above, you confirm that: • You consent to share operational information with MHRA's health system partners, as indicated in the statement above. • You have read MHRA's Operational Information Sharing Guidance • You are authorised by the proposed license holder to give this consent. Where you have chosen not to consent to MHRA sharing operational information in accordance with the Operational Information Sharing Guidance, this will not affect MHRA's rights to hold, process or share your information insofar as it is required or permitted to do so under any applicable law, statute, regulation or legislation. If you choose not to consent to share operational information in accordance with the Operational Information Sharing Guidance, you may still submit Marketing Authorisation and your current application will						
						SUBMIT		

- 8. Then click 'Submit' and continue your MAA as required per your application.
- 9. Once the application is submitted, and if you have selected '**Yes'** to share operational information, consent will have been given to share operational information with our health system partners.